CEO of Ovid Therapeutics Jeremy Levin believes drugs used for neurological diseases are on the cusp of more focused treatment, as cancer drugs were a decade ago. Photo: AP/Alastair Grant

Why this biotech start-up is going after rare neurological diseases

New York-based Ovid Therapeutics head says increased understanding in cancer treatment means ‘teaching fell into neurology’

Topic |   Business Insider

TOP PICKS

CEO of Ovid Therapeutics Jeremy Levin believes drugs used for neurological diseases are on the cusp of more focused treatment, as cancer drugs were a decade ago. Photo: AP/Alastair Grant
READ FULL ARTICLE